UCB
RELATED ARTICLES
Researcher Profile: Eddy Han-Burgess
Eddy Han-Burgess and his team are using a mix of mathematical modeling, big data and artificial intelligence in hopes of more quickly identifying the unique characteristics of someone’s condition.
Researcher Profile: Henrik Klitgaard
With nearly 30 years of experience in biopharmaceutical research, Dr. Henrik Klitgaard has dedicated his life to pursuing new and better treatments for patients with epilepsy.
Taking Control of Epilepsy
As the most common serious neurological condition in the U.S., epilepsy affects roughly 3.4 million Americans. It's what drives biopharmaceutical researchers to fight back with innovative medicines like targeted treatments that could transform the lives of patients living with the disease.
Pursuing Novel and Targeted Treatments for Epilepsy
Epilepsy is a complex condition, and it will take an equally complex approach to put an end to the disease. America's biopharmaceutical companies will not be satisfied until that goal is reached.
Researcher Profile: Luiz Miguel Camargo
As director of innovation networks at UCB, Dr. Luiz Miguel Camargo helps identify tools that researchers use to discover transformative medicines.
Researcher Profile: Victor Sloan
As vice president and development strategy lead at UCB, Victor Sloan has worked in the field of rheumatology since the early 1990's.
Tackling Epilepsy to Deliver Value to Patients
Brain diseases affect one in six people around the world. The range of conditions affecting the central nervous system – and how they impact the patient – is wide, making unlocking the science behind them complicated.
POPULAR ARTICLES
HIV/AIDS: From An Acute Fatal Disease to A Chronic, Manageable Condition
<p>The evolution of HIV/AIDS treatment is nothing short of remarkable. In the 1980s, HIV/AIDS was an acute fatal disease. Today it is a chronic, manageable condition thanks to the commitment of biopharmaceutical researchers, health care workers and advocates.</p>
READ MORE
Combatting Sickle Cell Disease with Cell & Gene Therapy
<p><span><span><span><a><span lang="EN"><span>America's biopharmaceutical companies are researching and developing new treatments to alleviate the tremendous burden of this devastating and painful disease and to improve the quality of life for sickle cell patients.</span></span></a></span></span></span></p>
READ MORE
Why Has Research into Alzheimer's Disease Been So Hard?
<p>Why, when we have seen such progress in our ability to treat other diseases, such as cancer, diabetes and HIV, has progress in Alzheimer's research been so difficult to achieve?</p>
READ MORE
5 Recent Developments Advancing Vaccines
As communities continue to grapple with the impact of COVID-19, vaccines have once again come to the forefront as a critical health care tool.
READ MORE
The Innovation Ecosystem Fuels Breakthroughs
Biopharmaceutical research companies are uniquely positioned to take the necessary risks to further advance research into safe and effective treatments for patients.
READ MORE
Understanding mRNA Vaccines
Scientists at Pfizer are breaking barriers with mRNA technology, one of the approaches used to develop COVID-19 vaccines.
READ MORE
Protecting Alzheimer's Research
15 million people will live with Alzheimer's by 2060. We're working to change that.
READ MORE